Journal Summary - Discover more summaries and articles from M3 India

Journal Summaries

Oncology

Dermatologic Oncology

Prognostic factors and survival for malignant conjunctival melanoma and squamous cell carcinoma over four decades

American Journal of Otolaryngology - Head and Neck Medicine and Surgery | Jun 15, 2019 Dermatologic Oncology

Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment

Journal of Clinical Oncology | Jun 13, 2019 Dermatologic Oncology

Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma

New England Journal of Medicine | Jun 10, 2019 Dermatologic Oncology

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAF^V600 mutation-positive melanoma (NeoCombi): A single-arm, open-label, single-centre, phase 2 trial

The Lancet Oncology | Jun 09, 2019 Dermatologic Oncology

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): A multicentre, phase 2, randomised, controlled trial

The Lancet Oncology | Jun 07, 2019 Dermatologic Oncology

Factors associated with time to surgery in melanoma: An analysis of the National Cancer Database

Journal of the American Academy of Dermatology | Jun 07, 2019 Dermatologic Oncology

Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data

Diabetes, Obesity and Metabolism | Jun 05, 2019 Dermatologic Oncology

Stromal inflammatory cells are associated with poorer prognosis in primary cutaneous melanoma

Human Pathology | Jun 01, 2019 Dermatologic Oncology

Mohs surgery for melanoma; a prospective multicenter study

Journal of the American Academy of Dermatology | May 31, 2019 Dermatologic Oncology

Incidence and risk factors of keratinocyte carcinoma after first solid organ transplant in Ontario, Canada

JAMA | May 27, 2019 Dermatologic Oncology

« Prev 1 … 28 29 30 31 32 … 57 Next »

Prognostic factors and survival for malignant conjunctival melanoma and squamous cell carcinoma over four decades

Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment

Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAF^V600 mutation-positive melanoma (NeoCombi): A single-arm, open-label, single-centre, phase 2 trial

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): A multicentre, phase 2, randomised, controlled trial

Factors associated with time to surgery in melanoma: An analysis of the National Cancer Database

Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data

Stromal inflammatory cells are associated with poorer prognosis in primary cutaneous melanoma

Mohs surgery for melanoma; a prospective multicenter study

Incidence and risk factors of keratinocyte carcinoma after first solid organ transplant in Ontario, Canada

BRI or BMI: What is More Efficient?

Enhancing Conventional Diabetes Management with Lifestyle and Nutritional Interventions

These Popular Snacks Linked a Decline in Mental Health

Awareness for COPD: MCQ challenge

Addressing Sleep Disorders with Integrative Solutions: From Pharmaceuticals to Natural Remedies

Prognostic factors and survival for malignant conjunctival melanoma and squamous cell carcinoma over four decades

Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment

Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): A single-arm, open-label, single-centre, phase 2 trial

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): A multicentre, phase 2, randomised, controlled trial

Factors associated with time to surgery in melanoma: An analysis of the National Cancer Database

Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data

Stromal inflammatory cells are associated with poorer prognosis in primary cutaneous melanoma

Mohs surgery for melanoma; a prospective multicenter study

Incidence and risk factors of keratinocyte carcinoma after first solid organ transplant in Ontario, Canada

BRI or BMI: What is More Efficient?

Enhancing Conventional Diabetes Management with Lifestyle and Nutritional Interventions

These Popular Snacks Linked a Decline in Mental Health

Awareness for COPD: MCQ challenge

Addressing Sleep Disorders with Integrative Solutions: From Pharmaceuticals to Natural Remedies

Select Specialty

Select Topic

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAF^V600 mutation-positive melanoma (NeoCombi): A single-arm, open-label, single-centre, phase 2 trial